Global Vascular Advances Clinical Trials with FTI's Follow-On Investment

Deal News | Jun 30, 2025 | Fast Track Initiative Inc

Global Vascular Advances Clinical Trials with FTI's Follow-On Investment

Fast Track Initiative Inc. (FTI) has made a follow-on investment in Global Vascular Inc. as part of the company's Series B financing round, which amounts to JPY 1 billion. The funds will support Global Vascular in initiating first-in-human clinical trials of its proprietary BioStealth™ drug-eluting stent, engineered to improve treatment for advanced peripheral arterial disease (PAD) in the below-the-knee segment. This technology aims to reduce foreign body responses and enhance vessel safety and patency. The trials mark a significant step toward regulatory approval in Japan and reflect FTI's commitment to fostering transformative medical technologies that address unmet needs. Global Vascular, based in Tokyo, is positioned to bring its vascular therapies to a broader market through a global clinical, regulatory, and commercialization strategy, initially focusing on Japan.

Sectors

  • Medical Devices
  • Venture Capital

Geography

  • Japan – Global Vascular is headquartered in Tokyo, and the clinical trials for the BioStealth stent are initially focused on the Japanese market.

Industry

  • Medical Devices – The article discusses Global Vascular's development of the BioStealth™ drug-eluting stent (DES), a medical device intended for treating peripheral arterial disease.
  • Venture Capital – Fast Track Initiative Inc. is a venture capital firm investing in the life science sector, demonstrating their role in this investment round.

Financials

  • JPY 1 billion – Total raised in Global Vascular's Series B financing round.

Participants

NameRoleTypeDescription
Global Vascular Inc.Target companyCompanyA Tokyo-based medical device company focused on developing next-generation vascular therapies.
Fast Track Initiative Inc. (FTI)InvestorCompanyA venture capital firm investing in early-stage life sciences companies, supporting the development of transformative medical technologies.
Kenta BitoPresident and CEO of Global VascularPersonLeader of Global Vascular, guiding the company through this critical phase of clinical trials and regulatory advancement.